Results 81 to 90 of about 2,758 (199)

Meningococcal Serogroup Y Meningitis Reveals Inborn Factor B Deficiency

European Journal of Immunology, Volume 56, Issue 2, February 2026.
We report a novel case of complete complement Factor B deficiency revealed by invasive meningococcal disease. Using combined functional and genetic analyses, we demonstrate that loss of Factor B abolishes alternative pathway activity despite detectable protein levels. These findings provide a mechanistic framework relevant to complement diagnostics and
Camille Bougeard, Eléonore Eskander, Paula Vieira Martins, Joan Bitan, Julia Roquigny, Christèle Kyheng, Tamazoust Guiddir, Véronique Frémeaux‐Bacchi, Cécile Gonnin, Carine ElSissy   +9 more
wiley   +1 more source

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Therapeutic Advances in Hematology, 2019
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj   +1 more source

Invited letter MUC4 mutations as an amplifier of complement‐mediated thrombosis in paroxysmal nocturnal haemoglobinuria

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Eng Soo Yap, Edwin Wei Sheng Thong, Cheryl Xiu Qi Lim   +2 more
wiley   +1 more source

Complement and transplant‐associated thrombotic microangiopathy: Current and future approaches

HemaSphere, Volume 10, Issue 4, April 2026.
Massimo Cugno, Francesco Onida, Bernhard Lämmle   +2 more
wiley   +1 more source

Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies

Journal of Comparative Effectiveness Research
This summary gives an overview of three published articles that report the results of research studies of ravulizumab, an approved treatment for people with atypical hemolytic uremic syndrome (often shortened to aHUS).
Michal Nowicki, Nikoleta Printza
doaj   +1 more source

Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Therapeutics and Clinical Risk Management, 2021
Carmelo Gurnari,1,2 Ishani Nautiyal,1 Simona Pagliuca1,3 1Department of Translational Hematology and Oncology Research, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedicine and Prevention, PhD in Immunology ...
Gurnari C, Nautiyal I, Pagliuca S
doaj  

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

Frontiers in Immunology, 2019
The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
Antonio M. Risitano, Antonio M. Risitano, Serena Marotta, Serena Marotta, Patrizia Ricci, Luana Marano, Camilla Frieri, Fabiana Cacace, Michela Sica, Austin Kulasekararaj, Austin Kulasekararaj, Rodrigo T. Calado, Phillip Scheinberg, Rosario Notaro, Regis Peffault de Latour, Regis Peffault de Latour   +15 more
doaj   +1 more source

Ravulizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study [PDF]

C5 inhibitor; Myasthenia gravis; ZilucoplanInhibidor de C5; Miastenia gravis; ZilucoplanInhibidor de C5; Miastènia gravis; ZilucoplanBackground: Generalized myasthenia gravis (gMG) is a chronic, unpredictable disease associated with high treatment and ...
Bresch, Saskia, Farmakidis, Constantine, freimer, miriam, genge, angela, Hewamadduma, Channa, Howard, James, Juntas Morales, Raúl   +6 more
core   +1 more source

Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience [PDF]

Introduction: Thymoma-associated myasthenia gravis (TAMG) accounts for 15-20% of all myasthenia gravis (MG) cases and is typically characterized by severe clinical manifestations and suboptimal response to conventional therapies.
Erra, Carmen, Falso, Silvia, Habetswallner, Federico, Iorio, Raffaele, Marini, Martina, Marini, Sofia, Meacci, Elisa   +6 more
core   +1 more source